ClinicalTrials.gg
CompletedNCT02162355Updated Sep 16, 2014

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

A Phase 1 interventional study of GLPG0634 50 mg and GLPG0634 100 mg in Healthy, sponsored by Galapagos NV. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-16.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The purpose of this multiple ascending dose study is to characterize the safety, tolerability, and the amount of GLPG0634 present in the blood and urine (pharmacokinetics) of once daily oral administrations of GLPG0634 at 3 different dose levels for 10 days in Japanese healthy subjects.

Furthermore, the study will compare the safety, tolerability, pharmacokinetics, and effects of GLPG0634 on mechanism of action-related parameters in the blood (pharmacodynamics) of once daily oral administrations of GLPG0634 given at one dose level for 10 days in Japanese vs Caucasian healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese or Caucasian subjects between 20-65 years of age (included)
  • Subjects must have a between 18-28 kg/m² (included)
  • Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead and laboratory profile

Exclusion criteria

Exclusion Criteria:

  • A subject with a known to ingredients of the study drug or a significant allergic reaction to any drug
  • Concurrent participation or participation within 3 months prior to the initial study drug administration in a drug/device or biologic research study
  • A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration
  • Subject expresses current desire to have (more) children
  • Female subject is less than 6 months post-partum, post-abortion or post lactation prior to study drug administration or is pregnant or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    GLPG0634 in Japanese subjects

    Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days

    Drug: GLPG0634 50 mg · Drug: GLPG0634 100 mg · Drug: GLPG0634 200 mg

  • Placebo comparator
    Placebo in Japanese healthy subjects

    Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days

    Drug: Placebo

  • Experimental
    GLPG0634 in Caucasian subjects

    In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days

    Drug: GLPG0634 200 mg

  • Placebo comparator
    Placebo in Caucasian healthy subjects

    In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days

    Drug: Placebo

Interventions

  • 2 tablets of 25 mg GLPG0634 once daily for 10 days

    Also known as: 50 mg GLPG0634 as tablets

  • 1 tablet of 100 mg GLPG0634 once daily for 10 days

    Also known as: 100 mg GLPG0634 as tablets

  • 2 tablets of 100 mg GLPG0634 once daily for 10 days

    Also known as: 200 mg GLPG0634 as tablets

  • DrugPlacebo

    1 or 2 matching placebo tablets once daily for 10 days

    Also known as: Placebo as matching tablets

06

What researchers measure

Primary outcomes

  1. The number of subjects with adverse events

    To evaluate the safety and tolerability of GLPG0634 versus placebo in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested in terms of adverse events (AEs)

    Time frame: From screening up to 10 days after last dose (Day 20)

  2. The number of subjects with abnormal laboratory parameters

    To evaluate the safety and tolerability of GLPG0634 versus placebo in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested in terms of abnormal laboratory parameters

    Time frame: From screening up to 10 days after last dose (Day 20)

  3. The number of subjects with abnormal vital signs

    To evaluate the safety and tolerability of GLPG0634 versus placebo in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested in terms of abnormal vital signs

    Time frame: From screening up to 10 days after last dose (Day 20)

  4. The number of subjects with abnormal electrocardiogram

    To evaluate the safety and tolerability of GLPG0634 versus placebo in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested in terms of abnormal electrocardiogram

    Time frame: From screening up to 10 days after last dose (Day 20)

  5. The number of subjects with abnormal physical examination

    To evaluate the safety and tolerability of GLPG0634 versus placebo in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested in terms of abnormal physical examination

    Time frame: From screening up to 10 days after last dose (Day 20)

  6. The amount of GLPG0634 and metabolite in plasma and urine

    To characterize the amount of GLPG0634 and metabolite in plasma and urine over time - pharmacokinetics (PK) - in Japanese subjects at different dose levels, and between Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested Safety Issue?: No

    Time frame: Between Day 1 before dosing and Day 13 (72 hours after last dose)

Secondary outcomes

  1. The amount of GLPG0634 mechanism-of-action-related biomarkers in blood

    To characterize the effects of GLPG0634 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - in Japanese and Caucasian subjects at the highest dose level of GLPG0634 tested

    Time frame: Between Day 1 before dosing and Day 11 (24 hours after last dose)

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jun 12, 2014
Start
Jun 2014
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Sep 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02162355
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Jun 12, 2014
Start date
Jun 2014
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Sep 16, 2014

Study contacts

Pille Harrison, MD
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion